Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.

IF 3 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI:10.1080/14796694.2024.2358670

Alexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D Lewis, Ketty Peris, Oliver Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, Patrick R LaFontaine, Gerasimos Konidaris, Denise Bury, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Timothy Bowler, Matthew G Fury, Aleksandar Sekulic

{"title":"Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.","authors":"Alexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D Lewis, Ketty Peris, Oliver Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, Patrick R LaFontaine, Gerasimos Konidaris, Denise Bury, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Timothy Bowler, Matthew G Fury, Aleksandar Sekulic","doi":"10.1080/14796694.2024.2358670","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC).Materials & methods: Eighty-four patients with laBCC received cemiplimab 350 mg every 3 weeks (up to 9 cycles). HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (QLQ-C30) and Skindex-16 questionnaires at baseline and each cycle. Mixed-effects repeated-measures models evaluated change from baseline across cycles.Results: Clinically meaningful improvement or maintenance was reported by 62-90% of patients on QLQ-C30 scales and by approximately 80% on Skindex-16 scales at Cycle 2, with consistent results at Cycle 9 except fatigue.Conclusion: Most cemiplimab-treated patients with laBCC reported improvement or maintenance of HRQoL with low symptom burden except fatigue.Clinical Trial Registration: ClinicalTrials.gov identifier NCT03132636, registered 28 April 2017.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508947/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2358670","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC).Materials & methods: Eighty-four patients with laBCC received cemiplimab 350 mg every 3 weeks (up to 9 cycles). HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (QLQ-C30) and Skindex-16 questionnaires at baseline and each cycle. Mixed-effects repeated-measures models evaluated change from baseline across cycles.Results: Clinically meaningful improvement or maintenance was reported by 62-90% of patients on QLQ-C30 scales and by approximately 80% on Skindex-16 scales at Cycle 2, with consistent results at Cycle 9 except fatigue.Conclusion: Most cemiplimab-treated patients with laBCC reported improvement or maintenance of HRQoL with low symptom burden except fatigue.Clinical Trial Registration: ClinicalTrials.gov identifier NCT03132636, registered 28 April 2017.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在一项 II 期临床试验中，接受 cemiplimab 治疗的局部晚期基底细胞癌患者的生活质量。

目的：评估经塞米单抗治疗的局部晚期基底细胞癌（laBCC）患者的健康相关生活质量（HRQoL）。材料与方法：84名局部晚期基底细胞癌（laBCC）患者接受了每3周一次、每次350毫克（最多9个周期）的cemiplimab治疗。在基线和每个周期使用欧洲癌症研究和治疗组织生活质量核心30（QLQ-C30）和Skindex-16问卷评估HRQoL。混合效应重复测量模型评估了各周期与基线相比的变化。结果：在第 2 个周期，62%-90% 的患者在 QLQ-C30 量表上、约 80% 的患者在 Skindex-16 量表上报告了有临床意义的改善或维持，在第 9 个周期，除疲劳外，结果一致。结论大多数接受过塞米单抗治疗的 laBCC 患者的 HRQoL 均有所改善或维持，除疲劳外症状负担较轻：ClinicalTrials.gov标识符NCT03132636，2017年4月28日注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.